.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,582,617

« Back to Dashboard

Claims for Patent: 7,582,617

Title:Myocardial perfusion imaging method
Abstract:The present invention provides a method for using the partial adenosine A.sub.2A receptor agonists having the following structure ##STR00001## in myocardiological perfusion imaging.
Inventor(s): Belardinelli; Luiz (Menlo Park, CA), Blackburn; Brent K. (Los Altos, CA), Gao; Zhenhai (San Jose, CA)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:11/070,768
Patent Claims: 1. A method of myocardial perfusion imaging of a mammal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A.sub.2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A.sub.2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(hydroxyme- thyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the dose is from 0.0002 to 0.009 mg/kg.

2. The method of claim 1, wherein the dose of CVT-3033 or CVT-3146 is from 0.10 to 5.0 .mu.g/kg.

3. The method of claim 1 wherein the route of administration of the compound that is a selective partial A.sub.2A adenosine receptor agonist is bolus.

4. The method of claim 1 wherein the selective partial A.sub.2A adenosine receptor agonist compound is formulated into a liquid.

5. The method of claim 1 wherein the compound that is a selective partial A.sub.2A adenosine receptor agonist is administered in a single dose.

6. The method of claim 1 wherein the compound that is a selective partial A.sub.2A adenosine receptor agonist is CVT-3033.

7. The method of claim 6 wherein the route of administration of CVT-3033 is bolus.

8. The method of claim 6 wherein the CVT-3033 is formulated into a liquid.

9. The method of claim 6 wherein the CVT-3033 is administered in a single dose.

10. The method of claim 6, wherein the dose of CVT-3033 is from 0.0002 to 0.009 mg/kg.

11. The method of claim 6, wherein the dose of CVT-3033 is from 0.10 to 5.0 .mu.g/kg.

12. A method for iincreasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A.sub.2A adenosine receptor agonist to a mammal, wherein the selective partial A.sub.2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(- hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.

13. The method of claim 12, wherein the method of administration is bolus.

14. The method of claim 12, wherein the dose of CVT-3033 is from 0.10 to 5.0 .mu.g/kg.

15. A method of myocardial perfusion imaging of a mannnal in need thereof, comprising administering a radionuclide and a dose of a compound that is a selective partial A.sub.2A adenosine receptor agonist with a short duration of action to a mammal in need thereof, and determining areas of insufficient blood flow, wherein the selective partial A.sub.2A adenosine receptor agonist is CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopurin-- 2-yl}pyrazol-4-yl) and wherein the dose is from 0.0002 to 0.009 mg/kg.

16. The method of claim 15, wherein the route of administration of CVT-3146 is bolus.

17. The method of claim 15, wherein the CVT-3146 is formulated into a liquid.

18. The method of claim 15, wherein the CVT-3146 is administered in a single dose.

19. The method of claim 15, wherein the dose of CVT-3146 is from 0.10 to 5.0 .mu.g/kg.

20. A method for increasing coronary blood flow in a mammal in need there of comprising administering a pharmaceutically effective amount of a partial A.sub.2A adenosine receptor agonist to the mammal, wherein the selective partial A.sub.2A adenosine receptor agonist is CVT-3033, also known as (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9-yl]-5-(- hydroxymethyl) oxolane-3,4-diol, or CVT-3146, also known as (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxola-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, wherein the pharmaceutically effective amount is from 0.0002 to 0.009 mg/kg.

21. The method of claim 20 wherein the dose of CVT-3146 is from 0.10 to 5.0 .mu.g/kg.

22. The method of claim 20, wherein the method of administration is bolus.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc